Korean disclosure
ST Pharm 237690ST Pharm reported preliminary Q3 2026 results (consolidated): Revenue of KRW 97.6 billion (+19.1% year over year), operating profit of KRW 15.7 billion (+6.6% year over year), net profit of KRW 900 million (-94.8% year over year).
Preliminary EarningsFiled
Unofficial English translation by ChickenStock; the Korean original prevails. Korean page · Original filing on DART ↗
Highlights
Structured dataST Pharm reported preliminary Q3 2026 results (consolidated): Revenue of KRW 97.6 billion (+19.1% year over year), operating profit of KRW 15.7 billion (+6.6% year over year), net profit of KRW 900 million (-94.8% year over year).
Written in code from the structured data of the filing. Reference information, not investment advice.
Key figures
- Period
- Q3 2026
- Basis
- Consolidated
- Revenue
- KRW 97.6 billion (+19.1% year over year)
- Operating profit
- KRW 15.7 billion (+6.6% year over year)
- Net profit
- KRW 900 million (-94.8% year over year)
Filing facts
- Filing type
- Preliminary Earnings
- Report name
- Preliminary Consolidated Operating Results (Fair Disclosure)
- Filed
- Oct 27, 2026
- Receipt number
- 20261027900160